Clinical Trials Logo

Filter by:
  • Temporarily not available  
  • « Prev · Page 3
NCT ID: NCT05436470 Temporarily not available - Pseudoaneurysm Clinical Trials

Treatment (Compassionate) Use of Device - PK Papyrus

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to evaluate the clinical use of the PK Papyrus Coronary Stent Graft System, a Humanitarian Use Device (HUD) approved by the FDA under a Humanitarian Device Exemption.

NCT ID: NCT05522569 Temporarily not available - Clinical trials for Acute Ischemic Stroke

Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)

EXPAND
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to use an intravenous infusion of allogeneic human mesenchymal stem cells (Allo-hMSCs) to treat an acute ischemic stroke condition.

NCT ID: NCT05565846 Temporarily not available - Clinical trials for Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves

NTX-001 to Repair Peripheral Nerve Transection(s)

Start date: n/a
Phase:
Study type: Expanded Access

The proposed use of NTX-001 for transections of upper extremity and facial peripheral nerves, acutely or planned.

NCT ID: NCT02606929 Temporarily not available - Multiple Sclerosis Clinical Trials

Use of Well Known Drugs for New Destination - MS Improvement (MSNT)

MSNT
Start date: January 2015
Phase: Phase 0
Study type: Expanded Access

The purpose of this expanded access retrospective study is to determine whether tetracyclines, statins and antimycotics are effective in improvement of life and health condition in the treatment of multiple sclerosis due to autoimmune disease (MS) in all his forms, specially in patients that show no response to commonly used treatments

NCT ID: NCT02572440 Temporarily not available - Clinical trials for Autologous Blood Transfusion

Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation

Start date: October 2014
Phase: Phase 4
Study type: Expanded Access

Perioperative blood loss continues to be a serious problem in complex aortic arch surgery using deep hypothermic circulatory arrest (DHCA). Major blood loss causes increased morbidity and mortality [1]. These patients often require transfusion of allogeneic blood products. It has been estimated shortages of blood supply in China will worsen [2]. Clinicians have made significant progress to decrease the quality of allogenic blood transfusion. Increasing postoperative hemorrhage risk of aortic arch patients undergoing DHCA may be related to CPB induced hemostatic defect, the use of the CPB is likely to contribute to coagulation factor lost and platelet dysfunction [3, 4]. We are aware of the potential benefit of aPRP, withdrawal of aPRP immediately before initiating CPB appears to be a promising approach because it avoids CPB-related platelet damage and limits post-CPB blood loss. So we adopted and used aPRP as a blood conservation technique to reduce blood transfusion in aortic arch surgery with DHCA. Autologous red blood cells were infused to maintain a HGB level above 100 g/L after heparin neutralizing activity. And aPRPs were transfused after heparin neutralizing activity as no active bleeding was observed. Our goal was to determine the effect between aPRP and homologous transfusion on perioperative bleeding during complex aortic arch surgery using DHCA.